IMMUNOCORE HLDGS ADS/1 (6YG) — Net Asset Quality Index
IMMUNOCORE HLDGS ADS/1 (6YG) has a Net Asset Quality Index of 35.7% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €1.07 Billion minus total liabilities of €686.24 Million yields net assets of €381.03 Million. A higher index indicates a stronger, lower-leverage balance sheet. See 6YG cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
IMMUNOCORE HLDGS ADS/1 Net Asset Quality Index Over Time (2022–2025)
This chart shows how IMMUNOCORE HLDGS ADS/1's Net Asset Quality Index has evolved across 4 annual periods from 2022 to 2025. As of December 2025, the index stands at 35.7%, representing net assets of €381.03 Million against total assets of €1.07 Billion EUR. Explore 6YG cash flow metrics to assess how effectively this company generates cash.
Annual Net Asset Quality Index for IMMUNOCORE HLDGS ADS/1 (2022–2025)
The table below presents the year-by-year Net Asset Quality Index for IMMUNOCORE HLDGS ADS/1 from 2022 to 2025, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see IMMUNOCORE HLDGS ADS/1 market capitalisation.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 35.7% | €381.03 Million | €1.07 Billion | €686.24 Million | ▼ 0.0 pp |
| 2024 | 35.7% | €360.72 Million | €1.01 Billion | €648.79 Million | ▼ -26.1 pp |
| 2023 | 61.8% | €368.84 Million | €597.00 Million | €228.16 Million | ▼ -2.6 pp |
| 2022 | 64.3% | €338.90 Million | €526.76 Million | €187.86 Million | — |